Actively Recruiting
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Led by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Updated on 2025-05-15
90
Participants Needed
2
Research Sites
501 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.
CONDITIONS
Official Title
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically proven solid tumor malignancy (except for small cell lung cancer and germ cell tumor)
- Karnofsky performance status of 60 or higher
- Presence of 1 to 10 brain metastases with no more than two lesions or cavities measuring 3 cm or larger
- Maximum diameter of brain metastasis or resection cavity no more than 6 cm
- Serum creatinine less than or equal to 3 mg/dL and creatinine clearance at least 30 ml/min
- Psychological ability and general health adequate to complete study requirements and follow-up
- Willingness to complete neurocognitive assessments as scheduled
- Women of childbearing potential must have a negative pregnancy test within 21 days before enrollment
- Women of childbearing potential and men must agree to use effective contraception before and for 4 months after last treatment
- Ability to provide written informed consent and speak English
You will not qualify if you...
- Diagnosis of glioma or other World Health Organization grade II through IV primary brain tumor
- Brain surgery within 14 days before enrollment
- Planned chemotherapy during radiosurgery
- Presence of leptomeningeal metastases
- More than one seizure per week during the past 2 months despite adequate anticonvulsant therapy
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Jefferson Health New Jersey
Sewell, New Jersey, United States, 08080
Not Yet Recruiting
2
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
Research Team
W
Wenyin Shi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here